Related Experiment Video
Updated: May 3, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal
Liza M Y Gelissen1, Martijn T Wijburg1, Eva M M Strijbis1
1MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location De Boelelaan, Amsterdam, the Netherlands.
Background:
Interferon beta therapy (IFN-β) can induce production of antibodies (NAbs) that may neutralize both therapeutic IFN-β and endogenous IFN-β, potentially impairing antiviral immunity.
Objectives:
To investigate whether NAbs against IFN-β occur in multiple sclerosis patients that developed natalizumab-associated progressive multifocal leukoencephalopathy (NTZ-PML).
Methods:
Seven NTZ-PML patients were matched with natalizumab-treated patients with prior IFN-β exposure. All were tested for NAbs against IFN-β in serum.
Results:
NAbs against IFN-β were absent in all NTZ-PML cases, but present in three matched patients.
Conclusions:
These findings do not suggest a contributing role for IFN-β NAbs in natalizumab-associated PML.
More Related Videos
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Related Concept Videos
Multiple Sclerosis l: Introduction
Inhibitors of Viral Protein Synthesis
Encephalitis ll: Pathophysiology
Arboviral Encephalitis